Tenderwize
Zurück zur Suche

Open-house rebate contracts for valproic acid (non-retarded form)

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 03, 2028 · 584 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Valproinsäure in nicht retardierter Darreichungsform, ATC N03AG01

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

62 / 100

Komplexität

58 / 100

Risikofaktoren

Paper documents sent to the wrong channel or not received as original duplicate copies by the stated deadline may be in...

Only pharmaceutical companies are eligible, and a signed declaration of reliability is mandatory.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Open-house rebate agreements for the medicinal product valproic acid in non-retarded dosage form, ATC N03AG01.
  • Supply contract for pharmaceutical products.
Vollständige Zusammenfassung anzeigen

This is an open-house pharmaceutical supply arrangement by AOK Bayern for valproic acid in non-retarded form (ATC N03AG01), not a competitive award procedure in the usual sense. The buyer intends to conclude identical, non-exclusive contracts with all interested pharmaceutical companies that meet the stated suitability requirement. The contract period runs from 2026-06-01 to 2028-05-31, with contract conclusion possible until 2028-04-03. Submission is possible electronically via DTVP with a qualified electronic signature or in paper form in duplicate originals; German language is required, and non-German documents must be submitted with German translation. No contract value is provided.

Risiken

Paper documents sent to the wrong channel or not received as original duplicate copies by the stated deadline may be in...

Only pharmaceutical companies are eligible, and a signed declaration of reliability is mandatory.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability must be submitted.
  • The signed contract and the completed annex 'Determination of the medicinal products covered by the contract' must be submitted.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate contracts for valproic acid (non-retarded form)

Single lot from structured data. Scope: open-house rebate agreements for pharmaceutical products containing valproic acid in non-retarded dosage form, ATC N03AG01. The arrangement is non-exclusive and identical for all qualifying pharmaceutical companies. Place of performance is Germany, Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

May 2026 - May 2028

Kategorie

Pharmaceutical products

Frist

Deadline Apr 03, 2028

Vergabedetails

Veröffentlichungsdatum
14 Apr 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
255761-2026

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30